Aberration in Structure of Brain Artery Responsible For Migraines: New Study

Brain Neuron

 

Incomplete Brain Arterial Network Found In Migraineurs (1)

Researchers from University of Pennsylvania’s Perelman School of Medicine are suggesting based on their recent study, that the network of arteries that supply blood to the brain is incomplete in those who suffer migraines. This impairs and creates asymmetries in cerebral blood flow that act as triggers for migraines.

The network of cerebral arteries consists of a series of connections between major arteries. This network with it’s connections is called ‘Circle of Willis’. The study found a strong association between incomplete network connections in the Circle of Willis thus depriving certain parts of the brain of blood flow and oxygen.

As per lead author of the study, Brett Cucchiara, MD, Associate Professor of Neurology, “People with migraine actually have differences in the structure of their blood vessels – this is something you are born with. These differences seem to be associated with changes in blood flow in the brain, and it’s possible that these changes may trigger migraine, which may explain why some people, for instance, notice that dehydration triggers their headaches.” (2)

The study also suggested that blood vessels in the brain played a rather different role in migraine condition than what was earlier believed. The structural aberration in blood supply caused by an incomplete Circle of Willis also increases a person’s susceptibility to abnormal neural activity and electrical pulse generation in the brain thus triggering migraines.

The study examined 170 people from three groups.

  • Group 1: A control group with no migraines or headaches
  • Group 2: Those suffering from migraines with aura
  • Group 3: Those with migraines without aura

A good percentage of persons in Groups 2 and 3 were found to have a common ground of incomplete Circle of Willis when compared to the control group.

MRI angiography was employed to examine blood vessel structure and a noninvasive magnetic resonance imaging method called Arterial Spin Labeling (ASL) was used to measure changes in cerebral blood flow during the study.

According to senior author, John Detre, MD, Professor of Neurology and Radiology, “Abnormalities in both the circle of Willis and blood flow were most prominent in the back of the brain, where the visual cortex is located. This may help explain why the most common migraine auras consist of visual symptoms such as seeing distortions, spots, or wavy lines.” (3)

The study suggests that at some point in the future more work on the role of the Circle of Willis will help design personalized treatment and therapy for patients.

SOURCES:

  1. Image credits: FreeDigitialPhotos.net: Image by Renjith krishnan; Web July 2013; http://www.freedigitalphotos.net/images/neuron-photo-p186134
  2. Migraines Associated With Variations in Structure of Brain Arteries; Science Daily News; Web July 2013; http://www.sciencedaily.com/releases/2013/07/130726191731.htm
  3. Abnormal Arteries May Trigger Migraines; Nationalpainreport.com; Web July 2013; http://americannewsreport.com/nationalpainreport/abnormal-arteries-may-trigger-migraines-8821061.html

DETAILS OF THE STUDY MAY BE HAD AT PLOS ONE:

Copyrights apply on this blog. Please refer copyright permissions. 

Advertisements

Acupressure Wristband Helps With Migraine Nausea

seaband_child

Acupressure Wristband Relieves Nausea During Migraines (1)

Aside from excruciating pain, nausea and/or vomiting is one of the most bothersome symptoms of migraines. Studies show that it is more common in occurrence than aura among migraineurs of both genders. A good 80% of migraineurs experience degrees of nausea during a migraine attack.

Thankfully, some testing from Berolina Clinic in Lohne, Germany has resulted in an acupressure wristband that subdues symptom of nausea when a migraine episode is underway. Dr. Zoltan Medgyessy, the leading headache physician of the clinic presented in the International Headache Congress 2013 in Boston the efficacy of the wristband. He demonstrated that the wristband applies pressure to point P6, the antiemetic point on the inner wrist providing fast relief from nausea for migraineurs.  (2)

The wristband was formed after a study on 41 patients who had averaged 33 days of migraines in the past 3 months and graded a nausea average of 6.2 on a scale of extreme 10. 83% of the nauseous migraineurs experienced a quick mitigation of the symptom to 2.0 out of 10 at approximately 28 minutes from time of wearing the wristband.

According to Dr. Medgyessy, “Acupressure wristbands are drug-free and that is an important advantage in using this therapy for migraine nausea as they have no risks for interaction with migraine drugs or the side effects commonly experienced with antiemetics, such as dizziness or tiredness. There are still many unknowns about migraine, making findings such as these an important stride toward improving the quality of life for those who suffer from the condition.” (3)

SOURCES:

  1. Image credit: Acupressure Wristband from Sea-Band; BaronePharmacy.com; July 2013; http://www.baronepharmacy.com.au/digestive-health/seaband-seaband-acupressure-wristband-childrens-pi-24108.html
  2. Acupressure Wristband Relieves Migraine Nausea; Medical News Today; Web July 2013; http://www.medicalnewstoday.com/releases/262536.php
  3. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress; EurekaAlert.com; Web July 2013; http://www.eurekalert.org/pub_releases/2013-06/rla-eoa061813.php

 Copyrights apply on this blog. Please refer copyright permissions.

FDA Grants Approval To Rizatriptan Benzoate ODT For Acute Migraine Treatment

Migraine Blog Rizatriptan ODT

Rizatriptan Benzoate ODT approved by FDA and launched in the market.  Image is not of said drug (1)

Pharmaceutical company Breckenridge’s drug Rizatriptan Benzoate has been given the green flag for immediate launch by the U.S Food and Drug Administration. The drug comes in the form of orally disintegrating tablet (ODT). It is available commercially in packs of potency/dosage 5 mg and 10 mg.

Breckenridge’s drug Rizatriptan Benzoate ODT is manufactured and supplied by Natco Pharma Limited. Just like Merck & Co. Inc’s Maxalt MLT, Rizatriptan Benzoate ODT is a prescription drug used in the management and treatment of acute migraine.

The FDA granted final ‘go ahead’ for the Abbreviated New Drug Application (ANDA) for Rizatriptan Benzoate ODT some nine months prior to expiration of the pediatric-exclusivity period for the challenged Orange Book patent (April 1, 2014).

‘Breckenridge’s patent challenge regarding Rizatriptan Benzoate Orally Disintegrating Tablets is a continuing part of its larger aggressive Paragraph IV strategy commenced a few years ago. Since the beginning of 2011, Breckenridge has filed twelve (12) Paragraph IV patent challenges and intends to continue that trend in the next several years, focusing on niche Paragraph IV opportunities with certain barriers to entry.’ (2)

SOURCES:

  1. Image Credit: FreeDigitalPhotos.net; Yellow Tablet; Image by rakratchada torsap; Web July 2013; http://www.freedigitalphotos.net/images/agree-terms.php?id=10096441
  2. Breckenridge Pharmaceutical, Inc. Announces Approval of Rizatriptan Benzoate ODT (Orally Disintegrating Tablets): BioSpace.com; Web July 2013;  http://www.biospace.com/news_story.aspx?StoryID=301892&full=1

Copyrights apply to this blog. Please refer copyright permissions.

OptiNose – New Migraine Treatment: Data Presented At IHC 2013

TE_optinoseOptiNose’s Breath Powered Nasal Delivery Device (1)

Drug delivery technology corporation OptiNose Inc. has presented results of a pivotal phase III TARGET study at the International Headache Congress at Boston comparing both the efficacy and the safety of it’s newly developed technology – the OptiNose Breath Powered nasal delivery device with other drug delivery systems and placebos. The abstracts are to be published in Cephalalgia, the Journal of the International Headache Society

The breath-powered device containing low dose sumatriptan was used to deliver the drug in patients experiencing moderate to severe migraine pain, and then compared to placebo administered via the same route later.

According to Ramy A. Mahmoud, M.D., M.P.H., Chief Operating Officer of OptiNose, “Various data we are presenting today will highlight how this novel delivery technology improves the delivery of medicine to hard-to-reach regions deep in the nasal cavity, how it can produce fast and efficient absorption of medicine into the blood, and how effective treatment with this technology can be. There are nearly 30 million migraine sufferers in the United States and many will be able to benefit from a new low-dose treatment that can rapidly provide effective pain relief with few adverse events.” (2)

Sections discussed in the International Headache Congress 2013 included:

  • Efficacy and Safety of a Novel Breath Powered Powder Sumatriptan Intranasal Treatment for Acute Migraine;
  • Data from a randomized, single-dose, four-way cross-over study assessing the absorption into the blood of sumatriptan intranasal powder administered using the  Breath Powered OptiNose drug delivery device compared to Imitrex® subcutaneous injection, Imitrex nasal spray and Imitrex oral tablets in healthy adult volunteers.
  • A review of evidence for human in vivo drug deposition patterns in different regions of the nose with devices intended to provide reliable and efficient drug delivery to upper/posterior nerve structures deep in the nasal cavity.

To know more about the TARGET study, please visit the OptiNose website link given below. (3)

SOURCES:

  1. Image Credit: Nansen Neuroscience Netwrok; Optinose: Novel Nasal Drug Delivery device; Web June 2013; http://www.nansenneuro.net/news/member-news/285-novel-nasal-drug-delivery-device.html
  2. OptiNose AS to Present Data Highlighting New Migraine Treatment at International Headache Congress; BioSpace.com; Web June 2013; http://www.biospace.com/news_story.aspx?StoryID=301426&full=1
  3. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating The Efficacy And Safety Of A Single 20 Mg Dose Of Sumatriptan Powder Delivered Intranasally With The Bi-Directional Device In Adults With Acute Migraine With Or Without Aura; TARGET Phase III Study; Optinose.com; Web June 2013; http://www.optinose.com/clinical-trials/target-clinical-trial-for-migraine

TO VIEW THE MULTIMEDIA CONTENT ASSOCIATED WITH THIS RELEASE, PLEASE CLICK: http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions/.

 Copyrights apply on this blog. Please read copyright permissions.